(Date:11/30/2009)...ANGELES, Nov. 30 /PRNewswire-Asia-FirstCall/ --,Ch...ard: CYXN; ,China Yongxin,Pharmaceuticals, or ,the...d,retailer of pharmaceuticals in Northeastern Chin...r distribution of medicines on the Essential Drug ...ormalized the nation,s Essential Drug,List which c...
(Date:11/30/2009)...re-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nas...g Administration (FDA) has granted orphan drug des...pridine phosphate, for the rare autoimmune disease...P has previously received orphan drug designation ...for Medicinal Products for Human Use of the Europe...
(Date:11/30/2009)...re-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Na...lass of platinum-based anti-tumor compounds, terme...or potency and activity compared to currently avai...ity to overcome cisplatin-resistance in cancer cel...tled "Novel Bis-platinum Complexes Endowed with an...
(Date:11/30/2009)...wswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), a,l...device research and,development outsourcing compan...announced that it had been selected to the Deloitt... consecutive year. The list recognizes the 50,fast..., and telecommunications,industries based on reven...
Breaking Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2...y researchers at the Carnegie Institution,* has fo...mune response, thereby allowing cancer cells to mu...ecules responsible for healthy T-cells, the bodys ...hed, permitting the invading cancer to spread. The...iseases such as multiple sclerosis. The work is pu...
...es, chief executive,officer of BioSante Pharmaceut...rma.com ) will be featured in an exclusive intervi...ember 26 at 10:30 a.m. EDT. The interview,will be ... September 26. The interview will cover topics in...ives, competitive edge, recent news, and milestone...
...eptember 26, 2007, SAN DIEGO, Sept. 24 Neurocrin...y that Neurocrine Biosciences will,present at the ...entation,will take place Wednesday, September 26, ...ific Time (PT). The presentation will be simultane... website at, http://www.neurocrine.com If you ar...
Other Biology Technology:Scientists discover how cancer may take hold 2WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals 2HISTOMOUNT SOLUTION from Invitrogen
Scaffold Software from Proteome Software Inc.
...ic peptide derived from the N-terminal region of t...teins. Specificity: Specific for the human occlud... Caco-2 cell lysates). Reactivity with rat mouse ...tern blotting Immunohistochemistry Immunofluoresce...
Rabbit Anti-ZFP-38 / RU49 Polyclonal Antibody, Unconjugated from CeMines
Biology Products: